TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01713452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse string closure
Description: 1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure
Description: 1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken.
Study: NCT00931814

Intervention type: OTHER
Group type: OTHER
Intervention: exercise training
Description: A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
Study: NCT03338855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2.
Study: NCT03404557

Intervention type: OTHER
Intervention: Proteomic analysis
Description: Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
Study: NCT01114100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
Study: NCT04139759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage
Description: In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
Study: NCT04104412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell
Description: 2\*10\^7
Study: NCT01352299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope blade
Description: Laryngoscopy performed with Macintosh Laryngoscope
Study: NCT00946816

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Nutritional Intervention
Study: NCT01556594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SC Glucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon 3 mg
Study: NCT02576691

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Study: NCT03578978

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to study subjects. Only blood will be obtained from study subjects.
Study: NCT02797665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
Study: NCT03833986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress management program
Description: Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
Study: NCT04236180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialised Paediatric Palliative Care (SPPC)
Description: All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
Study: NCT02519894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Scanning Calculator
Study: NCT04821700

Intervention type: BIOLOGICAL
Intervention: Carotid Stenosis
Description: To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
Study: NCT00245830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
Study: NCT00754715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Solution administered once orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution administered only once
Study: NCT01461928

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Induction Period)
Description: Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
Study: NCT01352299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MacCoy
Description: Laryngoscopy performed with MacCoy Laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller
Description: Laryngoscopy performed with Miller Laryngoscope
Study: NCT04942743

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI OF TMJ

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI OF TMJ
Study: NCT02862561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT01352299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrueView
Description: Laryngoscopy performed with TrueView laryngoscope
Study: NCT01379547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procalcitonin guided antibiotics treatment algorithm
Description: Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
Study: NCT01189812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: 300 mg one time per day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one time daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
Study: NCT02744391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Study: NCT01461928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Induction Period)
Description: Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Participants will receive rituximab according to the regimen specified in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab according to the regimen specified in individual arm.
Study: NCT03263858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Implantation of coronary stent in de novo coronary artery lesions
Study: NCT03761888

Intervention type: DIAGNOSTIC_TEST
Intervention: optic nerve sheath measurement and transcranial doppler
Description: evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value

Intervention type: DIAGNOSTIC_TEST
Intervention: optic nerve sheath measurement and transcranial doppler
Description: evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
Study: NCT01018134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% once daily
Description: Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% twice daily
Description: Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% once daily
Description: Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% once daily
Description: Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle once daily
Description: Vehicle topical spray administered to affected areas once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle twice daily
Description: Vehicle topical spray administered to affected areas twice daily for 28 days
Study: NCT02242435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Study: NCT03366558

Intervention type: DIAGNOSTIC_TEST
Intervention: UPDRS questionnaires
Description: UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.

Intervention type: DIAGNOSTIC_TEST
Intervention: UPDRS questionnaires
Description: UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.

Intervention type: DIAGNOSTIC_TEST
Intervention: 20-step walking test
Description: 20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)

Intervention type: DIAGNOSTIC_TEST
Intervention: 20-step walking test
Description: 20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)

Intervention type: DIAGNOSTIC_TEST
Intervention: 20-step walking test
Description: 20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
Study: NCT02557100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT02710123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-Threshold exercise prescription
Description: Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Structured stretching prescription
Description: Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
Study: NCT00611442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lubiprostone
Description: lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo gelcap, taken at noon the day prior to the colonoscopy
Study: NCT04051710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study: NCT02870075

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fed exercise
Description: Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasted exercise
Description: Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
Study: NCT01314170

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Susanna Implant
Description: device
Study: NCT02264665

Intervention type: DRUG
Intervention: sunitinib
Description: sunitinib 37.5mg/d orally

Intervention type: DRUG
Intervention: everolimus
Description: everolimus 10mg/d orally

Intervention type: DRUG
Intervention: chemotherapies recommended in france
Description: depends on the chemotherapy prescribed (IV)
Study: NCT02581956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No walking exercise
Description: no exercise
Study: NCT05989087

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF
Description: Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
Study: NCT04538235

Intervention type: PROCEDURE
Intervention: Thoracic Regional Analgesia
Description: In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.

Intervention type: PROCEDURE
Intervention: Thoracic Regional Analgesia
Description: In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
Study: NCT02465788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleTouch
Description: Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
Study: NCT01610440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: rehabilitation therapy plus human umbilical cord mesenchymal stem cells
Study: NCT02545660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLF Image
Description: At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Light Image
Description: At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
Study: NCT03443830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
Study: NCT02904824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose derived regenerative cells
Description: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: centrifuged autologous fat
Description: centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
Study: NCT03700385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOWA Approach Endocardial Ablation System
Description: Endocardial ablation using the IOWA Approach Endocardial Ablation System
Study: NCT01617252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow / Facial mask
Description: J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow / Facial mask
Description: J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
Study: NCT01853800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Study: NCT01559922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of up to 2 study treatments administered 6 weeks apart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artefill
Description: Administration of up to 2 study treatments administered 6 weeks apart
Study: NCT04022421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: the drug will be taken by one group of the patients daily at a dose of 400mg